Filtered By:
Condition: SARS
Drug: Dexamethasone
This page shows you your search results in order of date.
Order by Relevance | Date
Total 463 results found since Jan 2013.
Treatments for COVID-19
Annu Rev Med. 2023 Sep 18. doi: 10.1146/annurev-med-052422-020316. Online ahead of print.ABSTRACTThe treatment for COVID-19 has evolved rapidly since the start of the pandemic and now consists mainly of antiviral and immunomodulatory agents. Antivirals, such as remdesivir and nirmatrelvir-ritonavir, have proved to be most useful earlier in illness (e.g., as outpatient therapy) and for less severe disease. Immunomodulatory therapy, such as dexamethasone and interleukin-6 or Janus kinase inhibitors, are most useful in severe disease or critical illness. The role of anti-SARS-CoV-2 monoclonal antibodies has diminished because...
Source: Annual Review of Medicine - September 18, 2023 Category: General Medicine Authors: Hayden S Andrews Jonathan D Herman Rajesh T Gandhi Source Type: research
Multiple Organ Dysfunction Secondary to Herpes Simplex Virus -1 Reactivation After Treatment With Dexamethasone and Sarilumab for Covid-19 Disease
CONCLUSIONS: HSV-1 reactivation is common in COVID-19 and likely contributes to poorer clinical outcomes. The mechanism causing susceptibility to viral reactivation is not clearly defined, however, the development of critical illness induced immunosuppression via dysfunction of interferon and interleukin pathways is a likely mechanism. This effect could be perpetuated with immunosuppressant medications, although further research is needed to characterise this phenomenon.PMID:37593250 | PMC:PMC10429616 | DOI:10.2478/jccm-2023-0010
Source: Herpes - August 18, 2023 Category: Infectious Diseases Authors: Thomas Roe Sam Waddy Nikitas Nikitas Source Type: research
Improving COVID-19 Disease Severity Surveillance Measures: Statewide Implementation Experience
Ann Intern Med. 2023 May 16. doi: 10.7326/M23-0618. Online ahead of print.ABSTRACTMeasurement of the burden of COVID-19 on U.S. hospitals has been an important element of the public health response to the pandemic. However, because of variation in testing density and policies, the metric is not standardized across facilities. Two types of burdens exist, one related to the infection control measures that patients who test positive for SARS-CoV-2 require and one from the care of severely ill patients receiving treatment of COVID-19. With rising population immunity from vaccination and infection, as well as the availability o...
Source: Annals of Internal Medicine - May 15, 2023 Category: Internal Medicine Authors: Shira Doron Paul A Monach Catherine M Brown Westyn Branch-Elliman Source Type: research
SARS-CoV-2 spike protein induces endothelial dysfunction in 3D engineered vascular networks
J Biomed Mater Res A. 2023 Apr 8. doi: 10.1002/jbm.a.37543. Online ahead of print.ABSTRACTWith new daily discoveries about the long-term impacts of COVID-19, there is a clear need to develop in vitro models that can be used to better understand the pathogenicity and impact of COVID-19. Here, we demonstrate the utility of developing a model of endothelial dysfunction that utilizes human induced pluripotent stem cell-derived endothelial progenitors encapsulated in collagen hydrogels to study the effects of COVID-19 on the endothelium. These cells form capillary-like vasculature within 1 week after encapsulation and treating ...
Source: Biomed Res - April 8, 2023 Category: Research Authors: Brett Stern Peter Monteleone Janet Zoldan Source Type: research
Changes in PD-1- and CTLA-4-bearing blood lymphocytes in ICU COVID-19 patients treated with Favipiravir/Kaletra or Dexamethasone/Remdesivir: a pilot study
This study evaluated the frequency of whole blood lymphocytes expressing PD-1 and CTLA-4 in COVID-19 patients upon admission to the intensive care unit (ICU) (i.e., severe) or infection ward (i.e., moderate) and after 7 days of antiviral therapy. COVID-19 patients were treated with either favipiravir or Kaletra (FK group, 11 severe and 11 moderate) or dexamethasone plus remdesivir (DR group, 7 severe and 10 moderate) for 7 days in a pilot study. Eight healthy control subjects were also enrolled. The frequency of PD-1+ and CTLA-4+ lymphocytes in whole blood was evaluated by flow cytometry. Patients on DR therapy had shorter...
Source: Iranian Journal of Allergy, Asthma and Immunology - April 1, 2023 Category: Allergy & Immunology Authors: Esmaeil Mortaz Hamidreza Jamaati Neda K Dezfuli Hakime Sheikhzade Seyed MohammadReza Hashemian Neda Dalil Roofchayee Frazaneh Dastan Payam Tabarsi Gert Folkerts Johan Garssen Sharon Mumby Ian M Adcock Source Type: research
